Etanercept as prophylactic psoriatic therapy before interferon-α and ribavirin treatment for active hepatitis C infection
Etanercept as prophylactic psoriatic therapy before interferon-α and ribavirin treatment for active hepatitis C infection
复制标题
DOI：
10.1111/j.1365-2230.2009.03476.x
复制
发表时间：
2010-06-01
影响因子：
4.1
通讯作者：
Wu, J. J.
中科院分区：
文献类型：
--
作者：
Behnam, S. E.;Hindiyeh, R.;Wu, J. J.
P>患有牛皮癣和慢性丙型肝炎病毒（HCV）感染的患者是一个治疗挑战。使用甲氨蝶呤和阿维A进行全身性银屑病治疗可能具有肝毒性，而用于治疗丙型肝炎病毒的干扰素 (IFN)-α 可能会使银屑病恶化。依那西普可成功用于牛皮癣和丙型肝炎患者。据我们所知，这是首例使用依那西普预防性使用 IFN-α 和利巴韦林治疗的 HCV 患者预防银屑病发作的病例报告。
P>Patients with psoriasis and chronic hepatitis C virus (HCV) infection are a therapeutic challenge. Systemic psoriasis treatment with methotrexate and acitretin can be hepatotoxic, and interferon (IFN)-alpha for treatment of HCV can worsen psoriasis. Etanercept can be successfully used in patients with psoriasis and HCV. To our knowledge, this is the first case report of etanercept used prophylactically to prevent a psoriatic flare in a patient with HCV treated with IFN-alpha and ribavirin.